Literature DB >> 11805507

Residence time of netilmicin in tears.

Anna Claudia Scuderi1, Alessandra De Lazzari, Fausto Miano, Pietro Zola.   

Abstract

PURPOSE: To determine the concentration of netilmicin in tears after eye drop administration.
METHODS: A clinical study was carried out on 32 healthy volunteers. Subjects were divided into four groups and underwent tear collection at 5, 10, 20, and 60-minutes after drug administration, respectively. Tear samples were collected through capillary suction from the inferior conjunctival "cul-de-sac" and analyzed by high-pressure liquid chromatography (HPLC).
RESULTS: Netilmicin concentration in tears decreased after a first order kinetics, a best-fit curve was drawn and the minimum inhibitory concentration (MIC90) intersection for the most common ocular pathogens was calculated.
CONCLUSIONS: The extrapolation of the curve shows that the concentration of netilmicin on the ocular surface can be effective against microorganisms more than 120 minutes after eye drop instillation.

Mesh:

Substances:

Year:  2002        PMID: 11805507     DOI: 10.1097/00003226-200201000-00011

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers.

Authors:  Feng Wu; Xiuli Zhao; Xingang Li; Yimin Cui
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

2.  Cellular pharmacokinetic and pharmacodynamic analyses of ethacrynic acid: Implications in topical drug delivery in the eye.

Authors:  Cheng-Wen Lin; Pedro Gonzalez; Fan Yuan
Journal:  Mol Vis       Date:  2011-09-27       Impact factor: 2.367

3.  Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections.

Authors:  Yuko Hara; Atsushi Shiraishi; Takeshi Kobayashi; Yuko Kadota; Yuji Shirakata; Koji Hashimoto; Yuichi Ohashi
Journal:  Mol Vis       Date:  2009-05-08       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.